Literature DB >> 24707940

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

James M Bogenberger1, Devora Delman, Nanna Hansen, Riccardo Valdez, Veena Fauble, Ruben A Mesa, Raoul Tibes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24707940      PMCID： PMC4331188          DOI： 10.3109/10428194.2014.910657

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Authors:  Stefan P Glaser; Erinna F Lee; Evelyn Trounson; Philippe Bouillet; Andrew Wei; W Douglas Fairlie; David J Izon; Johannes Zuber; Amy R Rappaport; Marco J Herold; Warren S Alexander; Scott W Lowe; Lorraine Robb; Andreas Strasser
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

2.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors:  Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

3.  Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.

Authors:  Ann Zeuner; Francesca Pedini; Federica Francescangeli; Michele Signore; Gabriella Girelli; Agostino Tafuri; Ruggero De Maria
Journal:  Blood       Date:  2008-12-05       Impact factor: 22.113

Review 4.  Mitochondria: gatekeepers of response to chemotherapy.

Authors:  Kristopher A Sarosiek; Triona Ni Chonghaile; Anthony Letai
Journal:  Trends Cell Biol       Date:  2013-09-21       Impact factor: 20.808

5.  Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

Authors:  Joseph T Opferman; Hiromi Iwasaki; Christy C Ong; Heikyung Suh; Shin-ichi Mizuno; Koichi Akashi; Stanley J Korsmeyer
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

6.  Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.

Authors:  Twee Tsao; Yuexi Shi; Steven Kornblau; Hongbo Lu; Sergej Konoplev; Ansu Antony; Vivian Ruvolo; Yi Hua Qiu; Ninaxiang Zhang; Kevin R Coombes; Michael Andreeff; Kensuke Kojima; Marina Konopleva
Journal:  Ann Hematol       Date:  2012-08-15       Impact factor: 3.673

7.  Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.

Authors:  M Silva; C Richard; A Benito; C Sanz; I Olalla; J L Fernández-Luna
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

8.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

9.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Authors:  Rongqing Pan; Leah J Hogdal; Juliana M Benito; Donna Bucci; Lina Han; Gautam Borthakur; Jorge Cortes; Daniel J DeAngelo; Lakeisha Debose; Hong Mu; Hartmut Döhner; Verena I Gaidzik; Ilene Galinsky; Leonard S Golfman; Torsten Haferlach; Karine G Harutyunyan; Jianhua Hu; Joel D Leverson; Guido Marcucci; Markus Müschen; Rachel Newman; Eugene Park; Peter P Ruvolo; Vivian Ruvolo; Jeremy Ryan; Sonja Schindela; Patrick Zweidler-McKay; Richard M Stone; Hagop Kantarjian; Michael Andreeff; Marina Konopleva; Anthony G Letai
Journal:  Cancer Discov       Date:  2013-12-17       Impact factor: 39.397

10.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Authors:  J M Bogenberger; S M Kornblau; W E Pierceall; R Lena; D Chow; C-X Shi; J Mantei; G Ahmann; I M Gonzales; A Choudhary; R Valdez; J Camoriano; V Fauble; R E Tiedemann; Y H Qiu; K R Coombes; M Cardone; E Braggio; H Yin; D O Azorsa; R A Mesa; A K Stewart; R Tibes
Journal:  Leukemia       Date:  2014-01-23       Impact factor: 11.528
  10 in total
  41 in total

1.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

2.  Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.

Authors:  Xufeng Chen; Christina Glytsou; Hua Zhou; Sonali Narang; Denis E Reyna; Andrea Lopez; Theodore Sakellaropoulos; Yixiao Gong; Andreas Kloetgen; Yoon Sing Yap; Eric Wang; Evripidis Gavathiotis; Aristotelis Tsirigos; Raoul Tibes; Iannis Aifantis
Journal:  Cancer Discov       Date:  2019-05-02       Impact factor: 39.397

Review 3.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

Review 4.  Venetoclax-based therapies for acute myeloid leukemia.

Authors:  Veronica A Guerra; Courtney DiNardo; Marina Konopleva
Journal:  Best Pract Res Clin Haematol       Date:  2019-05-24       Impact factor: 3.020

5.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

6.  Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.

Authors:  Michael A Spinner; Alexey Aleshin; Marianne T Santaguida; Steven A Schaffert; James L Zehnder; A Scott Patterson; Christos Gekas; Diane Heiser; Peter L Greenberg
Journal:  Blood Adv       Date:  2020-06-23

Review 7.  Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.

Authors:  Prashant Sharma; Daniel A Pollyea
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 8.  BCL-2 inhibition in AML: an unexpected bonus?

Authors:  Marina Konopleva; Anthony Letai
Journal:  Blood       Date:  2018-07-23       Impact factor: 22.113

9.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

Review 10.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.